This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut

Agomab Therapeutics files for US IPO